Search results
Results from the WOW.Com Content Network
Antihypertensive agents comprise multiple classes of compounds that are intended to manage hypertension (high blood pressure). Antihypertensive therapy aims to maintain a blood pressure goal of <140/90 mmHg in all patients, as well as to prevent the progression or recurrence of cardiovascular diseases (CVD) in hypertensive patients with established CVD. [2]
A box of Plavix. Plavix is marketed worldwide in nearly 110 countries, with sales of US$6.6 billion in 2009. [45] It was the second-top-selling drug in the world in 2007 [46] and was still growing by over 20% in 2007. US sales were US$3.8 billion in 2008. [47]
The correct use and properly fitted graded compression stockings can reduce the rate of thrombosis by 50%. [ 15 ] [ 19 ] : 745–46 Contraindications for the use of antiembolism stockings include the presence of advanced peripheral and obstructive arterial disease, septic phlebitis, heart failure, open wounds, dermatitis and peripheral ...
[5] [non-primary source needed] The patient package insert issue was revisited in 1980 and in 1995 without conclusive action being taken. Finally, in January 2006, the FDA released a major revision to the patient package insert guidelines, the first in 25 years.
[20] A patient taking anticoagulants—aspirin, clopidogrel, ticagrelol and others—will stop taking them several days before, to prevent excessive bleeding during and after the operation. Warfarin is also stopped for the same reason and the patient starts taking heparin products after the INR falls below 2.0. [20] [21]
Damage is reversible for approximately 20 [4]-30 [5] minutes after complete obstruction of blood flow; thereafter myocardial cell death ensues and progresses as time passes. Therefore, complete and sustained restoration of blood flow must be as prompt as possible to ensure maximum salvage of functional myocardium, a principle expressed in the ...
An antiplatelet drug (antiaggregant), also known as a platelet agglutination inhibitor or platelet aggregation inhibitor, is a member of a class of pharmaceuticals that decrease platelet aggregation [1] and inhibit thrombus formation.
Prasugrel produces inhibition of platelet aggregation to 20 μM or 5 μM ADP, as measured by light transmission aggregometry. [23] Following a 60-mg loading dose of the drug, about 90% of patients had at least 50% inhibition of platelet aggregation by one hour. Maximum platelet inhibition was about 80%.